We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Biofluid Ribonucleic Acid Isolation Kit Launched

By LabMedica International staff writers
Posted on 20 Dec 2012
An isolation kit for the extraction of small ribonucleic acid (RNA) from serum, plasma, urine and other biofluids has been specifically optimized for such applications.

The new biofluids kit allows scientists to obtain high quality microRNA from virtually all types of biofluids in just 45 minutes and the workflow is completed in six simple steps without the use of hazardous chemicals such as phenol and chloroform.

The miRCURY RNA Isolation Kit – Biofluids (Exiqon; Vedbaek, Denmark) is optimized to work with company's highly sensitive miRCURY LNA Universal real-time microRNA polymerase chain reaction (qPCR) platform. More...
The Isolation Kit is ideal for use with urine samples together with Exiqon’s Toxicology Focus microRNA PCR Panels, and for serum and plasma samples with the Serum/Plasma Focus microRNA PCR Panels, or indeed any of the almost 2,000 prevalidated qPCR microRNA assays available. The Isolation Kit – Biofluids can be used with a centrifuge or a vacuum manifold is provided in pack sizes of 10 and 50 units.

The company offers a complete range of PCR products for microRNA analysis, which includes ready-to-use panels for genome-wide screening of human, mouse and rat microRNAs, numerous focus panels, the fully flexible Pick & Mix panels, spike-in kits, cDNA synthesis and PCR Master Mix kits, as well as unique qPCR data analysis software. Customers that have identified novel microRNAs can take advantage of Exiqon’s proprietary LNA chemistry and unique design algorithm through easy-to-use online tool for high quality design of custom microRNA qPCR assays.

Henrik M. Pfundheller, Senior Vice President Sales and Marketing at Exiqon, said, "Our customers want fully integrated systems that allow highly robust and sensitive microRNA profiling in difficult samples such as blood and urine, and we deliver the solution with this new kit. We have not only optimized the protocols to ensure the highest yield in the market but have also made sure that the sample does not contain any inhibitors which may jeopardize the downstream PCR analysis."

Related Links:

Exiqon




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.